# A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

> **NCT04495296** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Transcenta Therapeutics Co., Ltd.** · enrollment: 320 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** TST001
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04495296
- **Lead sponsor:** Suzhou Transcenta Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-13
- **Primary completion:** 2026-06-25
- **Final completion:** 2026-12-01
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04495296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04495296, "A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04495296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*